Skip to main content

Table 1 Demographic and clinical data

From: Antimicrobial therapy and assessing therapeutic response in culture-negative pyogenic vertebral osteomyelitis: a retrospective comparative study with culture-positive pyogenic vertebral osteomyelitis

 

CN group (n = 41)

CP group (n = 32)

p value a

Total (n = 73)

Age [year]

65.41 ± 11.60

61.83 ± 13.76

0.570

64.73 ± 11.61 (42-84)

Male sex

27 (65.9%)

17 (53.1%)

0.337

44 (60.3%)

BMI

22.97 ± 3.25

24.27 ± 3.75

0.120

23.54 ± 3.52

Underlying disease

 Diabetes mellitus

14 (34.1%)

7 (21.9%)

0.304

21 (28.8%)

 Rheumatic disease

3 (7.3%)

1 (3.1%)

0.626

4 (5.5%)

 Liver cirrhosis

2 (4.9%)

0 (0%)

0.501

2 (2.7%)

 Chronic kidney disease

1 (2.4%)

0 (0%)

1.000

1 (1.4%)

Alcohol

13 (31.7%)

4 (12.5%)

0.092

17 (23.3%)

Smoking

15 (36.6%)

6 (18.8%)

0.121

21 (28.8%)

History of spinal procedures

27 (65.9%)

18 (56.3%)

0.471

45 (61.6%)

 Epidural injection

25 (55.6%)

18 (50.0%)

0.659

43 (53.1%)

 Acupuncture [oriental medicine]

10 (24.4%)

4 (12.5%)

0.242

14 (19.2%)

Fever [°C, >  37.3]

11 (26.8%)

8 (25.0%)

1.000

19 (26.0%)

Neurological symptom

17 (41.5%)

20 (62.5%)

0.100

37 (50.7%)

Features of PVO

 Extent of affected lesion [level]

1.49 ± 0.93 (1-5)

2.09 ± 1.28 (1-5)

0.022

1.75 ± 1.13 (1-5)

 Epidural abscess

18 (43.9%)

27 (84.4%)

0.001

45 (61.6%)

 Psoas abscess

17 (41.5%)

13 (40.6%)

1.000

30 (41.1%)

 Paraspinal abscess

27 (65.6%)

23 (71.9%)

0.612

50 (68.5%)

Duration of hospital stay [days]

50.32 ± 19.96 (21-120)

62.88 ± 26.04 (26-143)

0.022

55.82 ± 23.51 (21-143)

Follow up period [months]

18.00 ± 11.16 (6-42)

16.38 ± 12.48 (6-63)

0.560

17.29 ± 11.70 (6-63)

Recurrence

3 (7.3%)

2 (6.3%)

1.000

5 (6.8%)

  1. Data are presented as the mean ± standard deviation or frequency, CN culture negative, CP culture positive, BMI body mass index, PVO pyogenic vertebral osteomyelitis, a p value between group CN and CP, p values of < 0.05 were considered statistically significant.